ESG News For VIVO PARTICIPACOES S/A

Report available at corporateresponsibility.unither.com

Funding will accelerate the development of breakthrough genetic tools and technologies including software, wetware, and artificial wombs to advance species preservation and restoration as well as further developing human genetic technologies

Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the company will donate 100,000 vials of Veklury® (remdesivir) to help address the recent surge of COVID-19 cases in Indonesia and 3,000 vials of Veklury to help patients hospitalized with COVID-19 in Armenia.“As cases of COVID-19 surge again around the world, and the pandemic continues to affect the lives of so many, we remain focused on ensuring that our medicines can reach patients that need them,” said Johanna Mercier, Chief Commercia

The Melanoma Research Alliance, the largest non-profit funder of melanoma research, is proud to announce $8.1 million in funding for 34 new research awards. The awards, issued near the start of Melanoma Awareness Month, provide critical funding to address urgent unmet needs in melanoma.“COVID-19 has impacted so much, including research and clinical trials. This investment in melanoma research is needed now more than ever,” said MRA Board Chair and Co-Founder Debra Black. “We’re proud to support

Company to use its novel gene editing technology to explore a potential in vivo gene therapy treatment for cystic fibrosis

Nonprofit Testing for America is advising historically black colleges and universities (HBCUs) in their COVID-19 testing strategies to support a safe reopeningSiemens Foundation, Siemens Healthineers and Siemens employees have donated more than $5.4 million in response to COVID-19 to advance healthcare equity in underserved communitiesThis initiative is also supported by the global Siemens relief fund program that was set up to help combat the COVID-19 crisis

Locations chosen based on the needs of underserved communities most vulnerable to COVID-19, advancing the Foundation’s commitment to equity

FTI Consulting, Inc. (NYSE:FCN) today announced the appointment of Rodolfo Araujo, a leading expert on corporate governance, proxy contests and high-profile M&A transactions, as a Senior Managing Director, the Americas Head of the Corporate Governance and Activism offering in the firm’s Strategic Communications segment and also a member of the Company’s Activism and M&A Solutions practice. He will initially be based in Washington, D.C., and will report to Bria